Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

405.64 +5.72 (+1.43%)
Streaming Delayed Price Updated: 3:07 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Why Is Vertex Pharmaceuticals Stock Sliding Today?
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery. 
Via Benzinga
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst
The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal. 
Via Investor's Business Daily
Is CRISPR Therapeutics a Buy in the New Bull Market?
CRISPR Therapeutics is a specialist in the hot technology of gene editing. 
Via The Motley Fool
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here's My Top Growth Stock to Buy Right Now
There doesn't appear to be a weak link with this great stock. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
As the adage goes, winners keep winning. 
Via The Motley Fool
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
3 Magnificent Stocks to Buy and Hold Forever
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
It's always tough to be compared to a giant. 
Via The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. 
Via Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
The company could maintain the momentum it gained last year. 
Via The Motley Fool
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The Best Stock to Invest $1,000 in Right Now
This stock has what it takes to be a big winner. 
Via The Motley Fool
2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today
These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
Despite A bump in the road, the biotech's future looks sunny. 
Via The Motley Fool
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
These stocks seem likely to keep up their winning ways. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
These businesses are on paths to extremely bright futures. 
Via The Motley Fool
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
These big winners of 2023 could keep their momentum going in the new year. 
Via The Motley Fool
These 2 Phenomenal Growth Stocks Can Make You Richer in 2024
One market-beating stock and one beaten-down stock look like tempting buys for very different reasons. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.